港股异动 | 荣昌生物(09995)现涨超3% RC18出海进度慢于预期国家医保目录仍可保证关键产品销售增长

智通财经07-16

智通财经APP获悉，荣昌生物(09995)现涨超3%，截至发稿，涨3.39%，报16.46港元，成交额1785.43万港元。消息面上，7月8日和9日，荣昌生物A股、H股分别累计下跌27%、35%。荣昌生物宣布目前公司各项业务正常推进、实控人拟增持最多2000万元人民币公司股份。此外，公司举行电话会议，向市场通报包括RC18国际合作进展、现金流情况以及海外专利到期等问题。建银国际发研报指，市场担忧...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2451954372?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-07-16 15:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2451954372","market":"us","top_or_hot":-1,"title":"港股异动 | 荣昌生物(09995)现涨超3% RC18出海进度慢于预期 国家医保目录仍可保证关键产品销售增长","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，荣昌生物(09995)现涨超3%，截至发稿，涨3.39%，报16.46港元，成交额1785.43万港元。消息面上，7月8日和9日，荣昌生物A股、H股分别累计下跌27%、35%。荣昌生物宣布目前公司各项业务正常推进、实控人拟增持最多2000万元人民币公司股份。此外，公司举行电话会议，向市场通报包括RC18国际合作进展、现金流情况以及海外专利到期等问题。建银国际发研报指，市场担忧...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1151457.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 荣昌生物(09995)现涨超3% RC18出海进度慢于预期 国家医保目录仍可保证关键产品销售增长</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 荣昌生物(09995)现涨超3% RC18出海进度慢于预期 国家医保目录仍可保证关键产品销售增长\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-16 15:46 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1151457.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，荣昌生物(09995)现涨超3%，截至发稿，涨3.39%，报16.46港元，成交额1785.43万港元。消息面上，7月8日和9日，荣昌生物A股、H股分别累计下跌27%、35%。荣昌生物宣布目前公司各项业务正常推进、实控人拟增持最多2000万元人民币公司股份。此外，公司举行电话会议，向市场通报包括RC18国际合作进展、现金流情况以及海外专利到期等问题。建银国际发研报指，市场担忧...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1151457.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2328871848.SGD","symbol_name":"Eastspring Investments - China A Shares Growth AS SGD","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1151457.html","article_id":"2451954372","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2451954372","pubTimestamp":1721115990,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，荣昌生物现涨超3%，截至发稿，涨3.39%，报16.46港元，成交额1785.43万港元。消息面上，7月8日和9日，荣昌生物A股、H股分别累计下跌27%、35%。荣昌生物宣布目前公司各项业务正常推进、实控人拟增持最多2000万元人民币公司股份。该行指，国家医保目录为关键产品销售增长提供避风港。该行称， 2024年内主要催化剂为RC18潜在出海，若能完成，则有助于显著提升股价。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688331":"荣昌生物","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","09995":"荣昌生物","BK1161":"生物科技","BK1574":"生物医药B类股","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","HSCEI":"国企指数","HSTECH":"恒生科技指数","YANG":"三倍做空富时中国ETF-Direxion","BK1583":"高瓴概念","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","07226":"XL二南方恒科","BK0239":"医药制造"},"translate_title":"Changes in Hong Kong stocks Rongchang Biotech (09995) is now up more than 3%. RC18's overseas progress is slower than expected. The national medical insurance catalog can still guarantee sales growth of key products","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688331":1,"07226":1,"09995":1,"HSCEI":1,"HSTECH":1,"YANG":1},"content_text":"智通财经APP获悉，荣昌生物(09995)现涨超3%，截至发稿，涨3.39%，报16.46港元，成交额1785.43万港元。消息面上，7月8日和9日，荣昌生物A股、H股分别累计下跌27%、35%。荣昌生物宣布目前公司各项业务正常推进、实控人拟增持最多2000万元人民币公司股份。此外，公司举行电话会议，向市场通报包括RC18国际合作进展、现金流情况以及海外专利到期等问题。建银国际发研报指，市场担忧主要集中在关键药物RC18的海外业务发展，即在全球权益授权许可方面的缺乏成功；公司是否能够达到市场对其设定的总收入同比增长50%的目标；荣昌生物的再融资能力和信用额度。该行指，国家医保目录为关键产品销售增长提供避风港。基于首季营收，预测其2024年第二季度总营收3.76亿元人民币，同比增长50%，环比增长14%；上半年总营收7.07亿元人民币将同比增长69%，环比增长8%。浦银国际则表示，考虑到公司海外三期第一阶段揭盲需要52周数据，揭盲时间预计为1Q25，在年内没有海外数据读出的情况下，认为年内完成RC18出海恐怕可能还存在一定难度。该行称， 2024年内主要催化剂为RC18潜在出海，若能完成，则有助于显著提升股价。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2451954372"}

港股异动 | 荣昌生物(09995)现涨超3% RC18出海进度慢于预期 国家医保目录仍可保证关键产品销售增长

精彩评论

港股异动 | 荣昌生物(09995)现涨超3% RC18出海进度慢于预期国家医保目录仍可保证关键产品销售增长